Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCFN2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,582
Award facts
- Contract value 100% obligated
- $16,581.81 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $16,581.81 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, awarded on December 22, 2025, with an ultimate completion date of January 14, 2026, was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. is a critical supplier within the federal pharmaceutical supply chain, holding SAM registration since July 2001 and demonstrating substantial federal contracting activity through numerous prior delivery orders.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a broader $30.3 billion acquisition strategy designed to provide recurring pharmaceutical and medical supply support to Department of Defense military healthcare facilities worldwide. The parent IDC, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription medications, biologics, and medical consumables. The contract positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting DoD healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FCFN2?
SPE2DR26FCFN2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 22, 2025.
How much is contract SPE2DR26FCFN2 worth?
The government has obligated $16,582 on SPE2DR26FCFN2.
Is contract SPE2DR26FCFN2 an order under another contract?
Yes. SPE2DR26FCFN2 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFN2 competed?
The extent of competition for SPE2DR26FCFN2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award